Halozyme Therapeutics (HALO) Times Interest Earned (2013 - 2026)
Halozyme Therapeutics (HALO) reported Times Interest Earned of $33.5 for Q1 2026, up 7.1% year-over-year from $31.28 in Q1 2025, and up 277.11% quarter-over-quarter from -$18.91 in Q4 2025.
Halozyme Therapeutics (HALO) Times Interest Earned (2013 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 14 years of Times Interest Earned data on file, last reported at $33.5 in Q1 2026.
- Times Interest Earned for Q1 2026 came in at $33.5, up 7.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.79 (down 18.77% YoY), and the FY2025 annual result was $25.87, down 15.1% from the prior year.
- Times Interest Earned rose to $33.5 in Q1 2026 per HALO's latest filing, from -$18.91 in the prior quarter.
- Over five years, Times Interest Earned peaked at $50.73 in Q3 2025 and troughed at -$18.91 in Q4 2025.
- A 5-year average of $24.57 and a median of $21.2 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned surged 99.72% in 2024, then plunged 148.93% in 2025.
- A 5-year view of Times Interest Earned shows it stood at $16.3 in 2022, then increased by 18.72% to $19.36 in 2023, then surged by 99.72% to $38.66 in 2024, then sank by 148.93% to -$18.91 in 2025, then soared by 277.11% to $33.5 in 2026.
- Business Quant data shows HALO's Times Interest Earned at $33.5 in Q1 2026, -$18.91 in Q4 2025, and $50.73 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -258.33 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 11.79 |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 33.50 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.50 |
| Dec 31, 2025 | -18.91 |
| Sep 30, 2025 | 50.73 |
| Jun 30, 2025 | 46.07 |
| Mar 31, 2025 | 31.28 |
| Dec 31, 2024 | 38.66 |
| Sep 30, 2024 | 36.07 |
| Jun 30, 2024 | 25.91 |
| Mar 31, 2024 | 21.20 |
| Dec 31, 2023 | 19.36 |
| Sep 30, 2023 | 19.60 |
| Jun 30, 2023 | 21.02 |
| Mar 31, 2023 | 11.84 |
| Dec 31, 2022 | 16.30 |
| Sep 30, 2022 | 11.08 |
| Jun 30, 2022 | 10.97 |
| Mar 31, 2022 | 43.02 |
| Dec 31, 2021 | 27.51 |
| Sep 30, 2021 | 43.09 |
| Jun 30, 2021 | 53.11 |